Biotech | August 17, 2021
Indian pharma’s vaccine opportunity at US $ 10-11 billion
Domestic market and developing countries will need doses of Indian vaccines
Domestic market and developing countries will need doses of Indian vaccines
The notification implies that any export of Rapid Antigen Kit will require a licence or permission from DGFT
The company has strong product launches both in India and overseas
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Filing for WHO Emergency Use Authorisation this month
This robust growth has come despite the raging pandemic for most part of the quarter
The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The company plans to enter the EU markets in FY22
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
Subscribe To Our Newsletter & Stay Updated
